Cell signalling pathways, driven by protein kinases are involved in the onset and progression of virtually all cancer types. As of 2021, 89 kinase inhibitor drugs have been approved, with over 150 in clinical trials and thousands in the preclinical stages.

oncology cancer cells
scientist using a microscope to examine an oncology sample

Kinomica’s services in Oncology drug development deliver identification of targets, mode of action studies, off-target effects, drug resistance mechanisms and improved patient stratification for Clinical Trials.

Talk to our Experts

To find out more about the technology behind Kinomica’s advanced bioinformatics and phosphoproteomics analytical methods, talk to our experts.

Contact Us

If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.

“Our groundbreaking technology driven by deep expertise and powerful insights provides a direct snapshot of protein and cell-signalling activity, with data that demonstrates we can predict drug response far more accurately than current gene mutation markers”

Anthony Sullivan, Business Development Director